XTLB

XTL Biopharmaceuticals Ltd. [XTLB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XTLB Stock Summary

Top 10 Correlated ETFs

XTLB

Top 10 Correlated Stocks

XTLB

In the News

XTLB Financial details

Company Rating
-
Market Cap
13.08M
Income
-3.44M
Revenue
-459K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
03 Jun 2024
P/E
-158.06
Forward P/E
-
PEG
5.71
P/S
-11.85
P/B
217.53
P/C
-
P/FCF
-2.71
Quick Ratio
13.62
Current Ratio
14.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.64
EPS next Y
-
EPS next Q
-
EPS this Y
-216.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
NAN%
Revenue Q/Q
-
EPS Q/Q
-40.87%
-
-
-
-
SMA20
-7.09%
SMA50
-
SMA100
-35.52%
Inst Own
-
Inst Trans
-
ROA
-129%
ROE
-112%
ROC
-0.32%
Gross Margin
100%
Oper. Margin
172%
Profit Margin
750%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-4.99
52W High
-
52W Low
-
RSI
44.04
Rel Volume
0.09
Avg Volume
769.44K
Volume
66.39K
Perf Week
-8.2%
Perf Month
-26.8%
Perf Quarter
-24.83%
Perf Half Y
-37.78%
-
-
-
-
Beta
1.026
-
-
Volatility
0.05%, 0.11%
Prev Close
-6.67%
Price
1.12
Change
-4.27%

Something similar

Top by Market Cap
VOO
VTI
NVDA
MIX.JO
BRH.DE
Top Correlated ETFs
IGTM.L
IGLT.L
INXG.L
SUOP.L
SUOG.L
Top Correlated Stocks
9416.T
FARM
BSFA.L
1402.TW
1414.T
Similar Market Cap
ATER
8161.HK
XXM.TO
TM1.L
SIF

Company Profile

Healthcare Biotechnology
  • Volume Average 769.44K
  • Market Capitalization 13.08M
  • Employee 8
  • CEO Mr. Shlomo Spokone Shalev
  • Headquarters Ramat Gan,IL
  • IPO Date 2005-09-01
  • Website https://www.xtlbio.com

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.